245 related articles for article (PubMed ID: 11194468)
41. In vivo diuretic effect of a new non-peptide arginine vasopressin antagonist, OPC-31260, in conscious rats.
Tsuboi Y; Ishikawa S; Fujisawa G; Okada K; Saito T
J Endocrinol; 1994 Nov; 143(2):227-34. PubMed ID: 7829988
[TBL] [Abstract][Full Text] [Related]
42. Syndrome of inappropriate antidiuretic hormone secretion secondary to trauma in a dog.
Cilli NM; Bellis T
J Vet Emerg Crit Care (San Antonio); 2022 Jan; 32(1):135-140. PubMed ID: 34657374
[TBL] [Abstract][Full Text] [Related]
43. Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats.
Hirano T; Yamamura Y; Nakamura S; Onogawa T; Mori T
J Pharmacol Exp Ther; 2000 Jan; 292(1):288-94. PubMed ID: 10604960
[TBL] [Abstract][Full Text] [Related]
44. [Vasopressin antagonists in treatment of hyponatremia].
Olszewski W; Głuszek J
Pol Arch Med Wewn; 2007 Aug; 117(8):356-62. PubMed ID: 18018383
[TBL] [Abstract][Full Text] [Related]
45. Vasopressin V2-receptor antagonists: panaceas for hyponatremia?
Kitiyakara C; Wilcox CS
Curr Opin Nephrol Hypertens; 1997 Sep; 6(5):461-7. PubMed ID: 9327205
[TBL] [Abstract][Full Text] [Related]
46. OPC-21268, an orally effective, nonpeptide arginine vasopressin V1 receptor antagonist reduces vasogenic brain edema.
Bemana I; Takahashi E; Nakamura T; Kuyama H; Nagao S
Acta Neurochir Suppl; 1997; 70():194-7. PubMed ID: 9416320
[TBL] [Abstract][Full Text] [Related]
47. Syndrome of inappropriate antidiuretic hormone secretion associated with congenital hydrocephalus in a dog.
Shiel RE; Pinilla M; Mooney CT
J Am Anim Hosp Assoc; 2009; 45(5):249-52. PubMed ID: 19723849
[TBL] [Abstract][Full Text] [Related]
48. [Etiology, diagnostics and therapy of hyponatremias].
Laczi F
Orv Hetil; 2008 Jul; 149(29):1347-54. PubMed ID: 18617466
[TBL] [Abstract][Full Text] [Related]
49. Use of conivaptan for refractory syndrome of inappropriate secretion of antidiuretic hormone in a pediatric patient.
Peters S; Kuhn R; Gardner B; Bernard P
Pediatr Emerg Care; 2013 Feb; 29(2):230-2. PubMed ID: 23546432
[TBL] [Abstract][Full Text] [Related]
50. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.
Serradeil-Le Gal C; Lacour C; Valette G; Garcia G; Foulon L; Galindo G; Bankir L; Pouzet B; Guillon G; Barberis C; Chicot D; Jard S; Vilain P; Garcia C; Marty E; Raufaste D; Brossard G; Nisato D; Maffrand JP; Le Fur G
J Clin Invest; 1996 Dec; 98(12):2729-38. PubMed ID: 8981918
[TBL] [Abstract][Full Text] [Related]
51. Treatment of brain edema with a nonpeptide arginine vasopressin V1 receptor antagonist OPC-21268 in rats.
Bemana I; Nagao S
Neurosurgery; 1999 Jan; 44(1):148-54; discussion 154-5. PubMed ID: 9894975
[TBL] [Abstract][Full Text] [Related]
52. Diagnosis of the syndrome of inappropriate secretion of antidiuretic hormone.
Holm EA; Bie P; Ottesen M; Ødum L; Jespersen B
South Med J; 2009 Apr; 102(4):380-4. PubMed ID: 19279540
[TBL] [Abstract][Full Text] [Related]
53. Employment of vasopressin receptor antagonists in management of hyponatraemia and volume overload in some clinical conditions.
Urso C; Brucculeri S; Caimi G
J Clin Pharm Ther; 2015 Aug; 40(4):376-85. PubMed ID: 25924179
[TBL] [Abstract][Full Text] [Related]
54. Dehydration effects of a V2 antagonist on endolymphatic hydrops in guinea pigs.
Egami N; Kakigi A; Takeda T; Yamasoba T
Hear Res; 2016 Feb; 332():151-159. PubMed ID: 26719142
[TBL] [Abstract][Full Text] [Related]
55. Role of atrial natriuretic peptide in the diuresis of a newborn infant with the syndrome of inappropriate antidiuretic hormone secretion.
Kojima T; Hirata Y; Umeda Y; Sato Y; Fukuda Y; Matsuzaki S; Iwase S; Kobayashi Y
Acta Paediatr Scand; 1989 Sep; 78(5):793-6. PubMed ID: 2531965
[TBL] [Abstract][Full Text] [Related]
56. Vasopressin receptor antagonist OPC-31260 prevents cerebral oedema after subarachnoid haemorrhage.
László FA; Varga C; Nakamura S
Eur J Pharmacol; 1999 Jan; 364(2-3):115-22. PubMed ID: 9932713
[TBL] [Abstract][Full Text] [Related]
57. Comparison of two aquaretic drugs (niravoline and OPC-31260) in cirrhotic rats with ascites and water retention.
Bosch-Marcé M; Poo JL; Jiménez W; Bordas N; Leivas A; Morales-Ruiz M; Muñoz RM; Pérez M; Arroyo V; Rivera F; Rodés J
J Pharmacol Exp Ther; 1999 Apr; 289(1):194-201. PubMed ID: 10087004
[TBL] [Abstract][Full Text] [Related]
58. Vasopressin receptor antagonist in the treatment of the syndrome of inappropriate antidiuretic hormone in general hospital practice.
Rajendran R; Grossman AB; Kar P
Endocr J; 2012; 59(10):903-9. PubMed ID: 22785335
[TBL] [Abstract][Full Text] [Related]
59. Vascular responses to vasopressin antagonists in man and rat.
Burrell LM; Phillips PA; Rolls KA; Buxton BF; Johnston CI; Liu JJ
Clin Sci (Lond); 1994 Oct; 87(4):389-95. PubMed ID: 7834989
[TBL] [Abstract][Full Text] [Related]
60. Vasopressin V2 receptor antagonists.
Verbalis JG
J Mol Endocrinol; 2002 Aug; 29(1):1-9. PubMed ID: 12200224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
